Jianting Wen
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Jianting Wen has a total of 35 co-authors. Here are the top co-authors by number of shared publications:
- Jian Liu
Department of Rheumatology and Immunology First Affiliated Hospital of Anhui University of Chinese Medicine Hefei Anhui China
12 shared publications - Lei Wan
The First Affiliated Hospital of Anhui University of Chinese Medicine, Hefei, China
6 shared publications - Ling Xin
The First Affiliated Hospital of Anhui University of Chinese Medicine, Hefei, Anhui 230038, China
6 shared publications - Fanfan Wang
Department of Rheumatology and Immunology First Affiliated Hospital of Anhui University of Chinese Medicine Hefei Anhui China
5 shared publications - Dan Huang
The First Affiliated Hospital of Anhui University of Chinese Medicine Hefei China
4 shared publications - Yanyan Fang
The First Affiliated Hospital of Anhui University of Chinese Medicine, Hefei, Anhui 230038, China
4 shared publications
Latest Publications
- Open Access
- 18 August 2026
- Published by Wiley in Phytotherapy Research
- Vol. 40 (10) , 6005-6042
Therapeutic Properties and Underlying Mechanisms of Traditional Chinese Medicine in Managing Rheumatoid Arthritis: An Integrative Review of Clinical and Molecular Findings
Traditional Chinese medicine (TCM) has a long‐standing history in the treatment of rheumatoid arthritis (RA), known as “Bi Zheng,” and offers a comprehensive therapeutic approach characterized by multi‐target and multi‐pathway mechanisms. Modern pharmacological research has demonstrated that bioactive compounds and herbal formulas derived from TCM (e.g., triptolide [TPL] from Tripterygium wilfordii and the Xinfeng Capsule [XFC]) effectively interfere with the complex pathogenesis of RA. These interventions modulate diverse pathological processes, including the suppression of pro‐inflammatory cytokines (e.g., TNF‐α, IL‐6, and IL‐1β), induction of apoptosis in hyperplastic synovial cells, and regulation of novel cell death pathways (such as ferroptosis and pyroptosis). Furthermore, TCM components exhibit potent antioxidant properties, inhibit pathological angiogenesis, ameliorate hypercoagulable states, and restore gut microbiota dysbiosis, which is increasingly recognized as a key environmental factor in RA development. Notably, emerging evidence highlights the critical role of non‐coding RNAs (ncRNAs) as mediators of these therapeutic effects. Concurrently, a growing body of clinical evidence from randomized controlled trials (RCTs), cohort studies, and real‐world data mining consistently confirms the significant efficacy and safety of TCM interventions in relieving RA symptoms, improving joint function, and reducing disease activity. By integrating preclinical and clinical findings, a robust evidence chain emerges, validating traditional TCM concepts through modern scientific rigor. Therefore, TCM represents a valuable resource for RA drug discovery and integrative treatment strategies. Further in‐depth investigation is needed into its specific molecular targets, optimal formulations, and long‐term clinical outcomes to facilitate its global translation and application.
- 18 August 2026
- Published by Wiley in Phytotherapy Research
- Vol. 40 (10) , 6005-6042
Open AccessTherapeutic Properties and Underlying Mechanisms of Traditional Chinese Medicine in Managing Rheumatoid Arthritis: An Integrative Review of Clinical and Molecular Findings
Traditional Chinese medicine (TCM) has a long‐standing history in the treatment of rheumatoid arthritis (RA), known as “Bi Zheng,” and offers a comprehensive therapeutic approach characterized by multi‐target and multi‐pathway mechanisms. Modern pharmacological research has demonstrated that bioactive compounds and herbal formulas derived from TCM (e.g., triptolide [TPL] from Tripterygium wilfordii and the Xinfeng Capsule [XFC]) effectively interfere with the complex pathogenesis of RA. These interventions modulate diverse pathological processes, including the suppression of pro‐inflammatory cytokines (e.g., TNF‐α, IL‐6, and IL‐1β), induction of apoptosis in hyperplastic synovial cells, and regulation of novel cell death pathways (such as ferroptosis and pyroptosis). Furthermore, TCM components exhibit potent antioxidant properties, inhibit pathological angiogenesis, ameliorate hypercoagulable states, and restore gut microbiota dysbiosis, which is increasingly recognized as a key environmental factor in RA development. Notably, emerging evidence highlights the critical role of non‐coding RNAs (ncRNAs) as mediators of these therapeutic effects. Concurrently, a growing body of clinical evidence from randomized controlled trials (RCTs), cohort studies, and real‐world data mining consistently confirms the significant efficacy and safety of TCM interventions in relieving RA symptoms, improving joint function, and reducing disease activity. By integrating preclinical and clinical findings, a robust evidence chain emerges, validating traditional TCM concepts through modern scientific rigor. Therefore, TCM represents a valuable resource for RA drug discovery and integrative treatment strategies. Further in‐depth investigation is needed into its specific molecular targets, optimal formulations, and long‐term clinical outcomes to facilitate its global translation and application.
- 22 May 2025
- Published by Springer Nature in Inflammation Research
- Vol. 74 (1) , 1-12
Crosstalk between N6-methyladenosine modification and ncRNAs in rheumatic diseases: therapeutic and diagnostic implications
Background In eukaryotic cells, N6-methyladenosine (m6A) is the most prevalent RNA methylation modification and plays a fundamental role in regulating diverse biological processes through the modulation of non-coding RNA (ncRNA) expression and activity. The role of m6A modification in developing rheumatic diseases is crucial but remains inadequately studied. Methods Characterized by pain and inflammation, rheumatic diseases like rheumatoid arthritis (RA), osteoarthritis (OA), ankylosing spondylitis (AS), and systemic lupus erythematosus (SLE) are autoimmune disorders. Recent findings emphasize the importance of m6A modifications and non-coding RNAs in the biological processes underlying rheumatic diseases. Results This review elucidates the fundamental concept of m6A modification and the associated research methodologies. Subsequently, it systematically consolidates modern knowledge on the influence of m6A regulators and m6A modification-related ncRNAs on rheumatic diseases, incorporating perspectives on traditional Chinese medicine interventions. Conclusions Offering a comprehensive overview of m6A-related ncRNAs in the context of rheumatic diseases, this review proposes new therapeutic avenues by targeting m6A modification pathways.
- 22 May 2025
- Published by Springer Nature in Inflammation Research
- Vol. 74 (1) , 1-12
Crosstalk between N6-methyladenosine modification and ncRNAs in rheumatic diseases: therapeutic and diagnostic implications
Background In eukaryotic cells, N6-methyladenosine (m6A) is the most prevalent RNA methylation modification and plays a fundamental role in regulating diverse biological processes through the modulation of non-coding RNA (ncRNA) expression and activity. The role of m6A modification in developing rheumatic diseases is crucial but remains inadequately studied. Methods Characterized by pain and inflammation, rheumatic diseases like rheumatoid arthritis (RA), osteoarthritis (OA), ankylosing spondylitis (AS), and systemic lupus erythematosus (SLE) are autoimmune disorders. Recent findings emphasize the importance of m6A modifications and non-coding RNAs in the biological processes underlying rheumatic diseases. Results This review elucidates the fundamental concept of m6A modification and the associated research methodologies. Subsequently, it systematically consolidates modern knowledge on the influence of m6A regulators and m6A modification-related ncRNAs on rheumatic diseases, incorporating perspectives on traditional Chinese medicine interventions. Conclusions Offering a comprehensive overview of m6A-related ncRNAs in the context of rheumatic diseases, this review proposes new therapeutic avenues by targeting m6A modification pathways.
- Open Access
- 16 May 2025
- Published by Frontiers Media SA in Frontiers in Immunology
- Vol. 16, 1557402
New insights into the role of cellular senescence and rheumatic diseases
Rheumatic disease is a chronic inflammatory disease that imposes significant societal and economic burdens. Accumulating evidence has demonstrated that cellular senescence plays an important role in inflammation-induced rheumatic diseases. Due to the lack of effective therapies, there is an urgent need for a deeper understanding of the etiopathogenesis of rheumatic diseases. In this review, we systematically summarized the role of cellular senescence in rheumatic diseases. We first focused on the mechanisms and hallmarks of cellular senescence, and then summarized evidence that can induce or aggravate cellular senescence, as well as related signaling pathways. Next, we discussed the mechanisms of interaction between cellular senescence and rheumatic diseases. Additionally, we focused on and elucidated the mechanisms and impacts of chondrocyte senescence and mesenchymal stem cell (MSC) senescence in osteoarthritis (OA) and systemic lupus erythematosus (SLE), respectively. Finally, we highlighted the potential of therapies targeting senescent cells in rheumatic diseases as a strategy, especially the multi-target effect of traditional Chinese medicine.
- 16 May 2025
- Published by Frontiers Media SA in Frontiers in Immunology
- Vol. 16, 1557402
Open AccessNew insights into the role of cellular senescence and rheumatic diseases
Rheumatic disease is a chronic inflammatory disease that imposes significant societal and economic burdens. Accumulating evidence has demonstrated that cellular senescence plays an important role in inflammation-induced rheumatic diseases. Due to the lack of effective therapies, there is an urgent need for a deeper understanding of the etiopathogenesis of rheumatic diseases. In this review, we systematically summarized the role of cellular senescence in rheumatic diseases. We first focused on the mechanisms and hallmarks of cellular senescence, and then summarized evidence that can induce or aggravate cellular senescence, as well as related signaling pathways. Next, we discussed the mechanisms of interaction between cellular senescence and rheumatic diseases. Additionally, we focused on and elucidated the mechanisms and impacts of chondrocyte senescence and mesenchymal stem cell (MSC) senescence in osteoarthritis (OA) and systemic lupus erythematosus (SLE), respectively. Finally, we highlighted the potential of therapies targeting senescent cells in rheumatic diseases as a strategy, especially the multi-target effect of traditional Chinese medicine.
- 29 December 2023
- Published by Elsevier in Journal of Ethnopharmacology
- Vol. 323, 117677
Xinfeng capsule inhibits lncRNA NONHSAT227927.1/TRAF2 to alleviate NF-κB-p65-induced immuno-inflammation in ankylosing spondylitis
- 29 December 2023
- Published by Elsevier in Journal of Ethnopharmacology
- Vol. 323, 117677
Xinfeng capsule inhibits lncRNA NONHSAT227927.1/TRAF2 to alleviate NF-κB-p65-induced immuno-inflammation in ankylosing spondylitis
- Open Access
- 1 January 2023
- Published by Wiley in BioMed Research International
- Vol. 2023 (1) , 1019290
Traditional Chinese Medicine Compound Preparations Are Associated with Low Disease‐Related Complication Rates in Patients with Rheumatoid Arthritis: A Retrospective Cohort Study of 11,074 Patients
Objective. To evaluate whether traditional Chinese medicine compound preparations (TCMCPs) are associated with rheumatoid arthritis‐ (RA‐) related complications (including readmission, Sjogren’s syndrome, surgical treatment, and all‐cause death) in patients with RA. Methods. Clinical outcome data were retrospectively collected from patients with RA discharged from the Department of Rheumatology and Immunology of the First Affiliated Hospital of Anhui University of Chinese Medicine from January 2009 to June 2021. The propensity score matching method was used to match baseline data. Multivariate analysis was conducted to analyze sex, age, the incidence of hypertension, diabetes, and hyperlipidemia and identify the risk of readmission, Sjogren’s syndrome, surgical treatment, and all‐cause death. Users of TCMCP and nonusers of TCMCP were defined as the TCMCP and non‐TCMCP groups, respectively. Results. A total of 11,074 patients with RA were included in the study. The median follow‐up time was 54.85 months. After propensity score matching, the baseline data of TCMCP users corresponded with those of non‐TCMCP users, with 3517 cases in each group. Retrospective analysis revealed that TCMCP significantly reduced clinical, immune, and inflammatory indices in patients with RA, and these indices were highly correlated. Notably, the composite endpoint prognosis for treatment failure in TCMCP users was better than that in non‐TCMCP users (HR = 0.75 (0.71‐0.80)). The risk of RA‐related complications in TCMCP users with high‐exposure intensity (HR = 0.669 (0.650‐0.751)) and medium‐exposure intensity (HR = 0.796 (0.691‐0.918)) was significantly lower than those in non‐TCMCP users. An increase in exposure intensity was associated with a concomitant decrease in the risk of RA‐related complications. Conclusion. The use of TCMCPs, as well as long‐term exposure to TCMCPs, may lower RA‐related complications, including readmission, Sjogren’s syndrome, surgical treatment, and all‐cause death, in patients with RA.
- 1 January 2023
- Published by Wiley in BioMed Research International
- Vol. 2023 (1) , 1019290
Open AccessTraditional Chinese Medicine Compound Preparations Are Associated with Low Disease‐Related Complication Rates in Patients with Rheumatoid Arthritis: A Retrospective Cohort Study of 11,074 Patients
Objective. To evaluate whether traditional Chinese medicine compound preparations (TCMCPs) are associated with rheumatoid arthritis‐ (RA‐) related complications (including readmission, Sjogren’s syndrome, surgical treatment, and all‐cause death) in patients with RA. Methods. Clinical outcome data were retrospectively collected from patients with RA discharged from the Department of Rheumatology and Immunology of the First Affiliated Hospital of Anhui University of Chinese Medicine from January 2009 to June 2021. The propensity score matching method was used to match baseline data. Multivariate analysis was conducted to analyze sex, age, the incidence of hypertension, diabetes, and hyperlipidemia and identify the risk of readmission, Sjogren’s syndrome, surgical treatment, and all‐cause death. Users of TCMCP and nonusers of TCMCP were defined as the TCMCP and non‐TCMCP groups, respectively. Results. A total of 11,074 patients with RA were included in the study. The median follow‐up time was 54.85 months. After propensity score matching, the baseline data of TCMCP users corresponded with those of non‐TCMCP users, with 3517 cases in each group. Retrospective analysis revealed that TCMCP significantly reduced clinical, immune, and inflammatory indices in patients with RA, and these indices were highly correlated. Notably, the composite endpoint prognosis for treatment failure in TCMCP users was better than that in non‐TCMCP users (HR = 0.75 (0.71‐0.80)). The risk of RA‐related complications in TCMCP users with high‐exposure intensity (HR = 0.669 (0.650‐0.751)) and medium‐exposure intensity (HR = 0.796 (0.691‐0.918)) was significantly lower than those in non‐TCMCP users. An increase in exposure intensity was associated with a concomitant decrease in the risk of RA‐related complications. Conclusion. The use of TCMCPs, as well as long‐term exposure to TCMCPs, may lower RA‐related complications, including readmission, Sjogren’s syndrome, surgical treatment, and all‐cause death, in patients with RA.
- Open Access
- 3 August 2022
- Published by Wiley in Evidence-Based Complementary and Alternative Medicine
- Vol. 2022, 1-10
Traditional Chinese Medicine Is Associated with Reduced Risk of Readmission in Rheumatoid Arthritis Patients with Anemia: A Retrospective Cohort Study
Objective. This study aimed to analyze the effect of traditional Chinese medicine (TCM) on the risk of readmission for rheumatoid arthritis (RA) patients with anemia. Methods. In this study, 893 hospitalized RA patients were followed up by telephone. A retrospective cohort study was conducted using propensity score matching (PSM). The Cox proportional hazards model was used to assess the influence of various factors on the risk of readmission for RA patients with anemia. The Kaplan–Meier survival curve was utilized to analyze the effect of TCM intervention time on readmission. Results. The incidence of anemia was 58.08% (471/811) in RA patients. After 1 : 1 PSM, 328 RA patients with anemia and 328 RA patients without anemia were finally included in our study. The readmission rate of anemia patients was higher than that of patients without anemia ( ). The readmission rate of RA patients with anemia was obviously lower in the TCM group than in the non-TCM group ( ). The Cox proportional hazards model showed TCM as an independent protective factor as it decreased the risk of readmission by 50% (HR = 0.50, 95% CI = 0.27–0.94, ) in RA patients with anemia. In addition, the risk of readmission was dramatically diminished in the high-exposure subgroup (TCM > 12 months) compared with the low-exposure subgroup (TCM ≤ 12 months) (log-rank ). Conclusion. TCM, as a protective factor, is associated with a reduced risk of readmission in RA patients with anemia.
- 3 August 2022
- Published by Wiley in Evidence-Based Complementary and Alternative Medicine
- Vol. 2022, 1-10
Open AccessTraditional Chinese Medicine Is Associated with Reduced Risk of Readmission in Rheumatoid Arthritis Patients with Anemia: A Retrospective Cohort Study
Objective. This study aimed to analyze the effect of traditional Chinese medicine (TCM) on the risk of readmission for rheumatoid arthritis (RA) patients with anemia. Methods. In this study, 893 hospitalized RA patients were followed up by telephone. A retrospective cohort study was conducted using propensity score matching (PSM). The Cox proportional hazards model was used to assess the influence of various factors on the risk of readmission for RA patients with anemia. The Kaplan–Meier survival curve was utilized to analyze the effect of TCM intervention time on readmission. Results. The incidence of anemia was 58.08% (471/811) in RA patients. After 1 : 1 PSM, 328 RA patients with anemia and 328 RA patients without anemia were finally included in our study. The readmission rate of anemia patients was higher than that of patients without anemia ( ). The readmission rate of RA patients with anemia was obviously lower in the TCM group than in the non-TCM group ( ). The Cox proportional hazards model showed TCM as an independent protective factor as it decreased the risk of readmission by 50% (HR = 0.50, 95% CI = 0.27–0.94, ) in RA patients with anemia. In addition, the risk of readmission was dramatically diminished in the high-exposure subgroup (TCM > 12 months) compared with the low-exposure subgroup (TCM ≤ 12 months) (log-rank ). Conclusion. TCM, as a protective factor, is associated with a reduced risk of readmission in RA patients with anemia.
- Open Access
- 23 March 2022
- Published by Wiley in Evidence-Based Complementary and Alternative Medicine
- Vol. 2022, 1-10
Exploration of the Immuno-Inflammatory Potential Targets of Xinfeng Capsule in Patients with Ankylosing Spondylitis Based on Data Mining, Network Pharmacology, and Molecular Docking
Objective. This study aimed to ascertain the immuno-inflammatory molecular targets of Xinfeng capsules (XFC) in the treatment of ankylosing spondylitis (AS) based on data mining, network pharmacology, and molecular docking. Methods. The efficacy of XFC in the treatment of AS was assessed by clinical data mining. Network pharmacology was utilized to establish a network of the targets for XFC active ingredients in the treatment of AS. The binding mode and affinity of XFC active ingredients to the key targets for AS were predicted using molecular docking. Results. XFC significantly diminished immuno-inflammatory indicators of AS. In total, 208 targets of XFC were obtained from the TCMSP database and 629 disease targets of AS were screened from the GeneCards database, which were intersected to yield 57 targets of XFC in the treatment of AS. Protein-protein interaction, gene ontology, and Kyoto genome encyclopedia analyses showed that XFC might activate TNF and NF-κB signaling pathways. Quercetin, kaempferol, triptolide, and formononetin had free binding energies<-9kcal/mol to inflammatory targets (TNF and PTGS2) in the molecular docking analysis of XFC-active ingredients, indicating that TNF and PTGS2 might be the targets of the action of XFC. Conclusions. Collectively, XFC had a significant therapeutic effect on AS. Specifically, the active ingredients of XFC, including quercetin, kaempferol, triptolide, and formononetin, inhibited the inflammatory response in AS by downregulating TNF and PTGS2 in the TNF and NF-κB signaling pathways.
- 23 March 2022
- Published by Wiley in Evidence-Based Complementary and Alternative Medicine
- Vol. 2022, 1-10
Open AccessExploration of the Immuno-Inflammatory Potential Targets of Xinfeng Capsule in Patients with Ankylosing Spondylitis Based on Data Mining, Network Pharmacology, and Molecular Docking
Objective. This study aimed to ascertain the immuno-inflammatory molecular targets of Xinfeng capsules (XFC) in the treatment of ankylosing spondylitis (AS) based on data mining, network pharmacology, and molecular docking. Methods. The efficacy of XFC in the treatment of AS was assessed by clinical data mining. Network pharmacology was utilized to establish a network of the targets for XFC active ingredients in the treatment of AS. The binding mode and affinity of XFC active ingredients to the key targets for AS were predicted using molecular docking. Results. XFC significantly diminished immuno-inflammatory indicators of AS. In total, 208 targets of XFC were obtained from the TCMSP database and 629 disease targets of AS were screened from the GeneCards database, which were intersected to yield 57 targets of XFC in the treatment of AS. Protein-protein interaction, gene ontology, and Kyoto genome encyclopedia analyses showed that XFC might activate TNF and NF-κB signaling pathways. Quercetin, kaempferol, triptolide, and formononetin had free binding energies<-9kcal/mol to inflammatory targets (TNF and PTGS2) in the molecular docking analysis of XFC-active ingredients, indicating that TNF and PTGS2 might be the targets of the action of XFC. Conclusions. Collectively, XFC had a significant therapeutic effect on AS. Specifically, the active ingredients of XFC, including quercetin, kaempferol, triptolide, and formononetin, inhibited the inflammatory response in AS by downregulating TNF and PTGS2 in the TNF and NF-κB signaling pathways.
- Open Access
- 11 March 2022
- Published by Wroclaw Medical University in Advances in Clinical and Experimental Medicine
- Vol. 31 (7) , 781-788
Knockdown of circular RNA hsa_circ_0003307 inhibits synovial inflammation in ankylosing spondylitis by regulating the PI3K/AKT pathway
Background. Ankylosing spondylitis (AS) has a high disability rate, and an early diagnosis is difficult. Objectives. To explore the possible functions and underlying mechanism of circular RNAs Homo sapiens (hsa)_circ_0003307 in ankylosing spondylitis. Materials and methods. The hsa_circ_0003307 expression levels were investigated in the peripheral blood mononuclear cells (PBMCs) of 30 AS patients and 30 healthy controls (HC) using quantitative reverse transcription polymerase chain reaction (qRT-PCR) analysis. Primary fibroblast-like synoviocytes (FLS) were separated from synovial tissues, established as cell lines and cultured for subsequent cell experiments involving transfection with different vectors. The qRT-PCR analysis was used for evaluating the levels of hsa_circ_0003307 in AS-FLS. Phosphoinositide 3-kinase (PI3K)/protein kinase B (AKT) pathway-related protein levels were measured using western blotting and immunofluorescence. Enzyme-linked immunosorbent assay (ELISA) was used to detect the levels of inflammatory cytokines. Spearman's correlation analysis was used to assess the correlation between hsa_circ_0003307 and clinical characteristics. Results. The expression level of hsa_circ_0003307 was significantly high in AS patients and was positively associated with erythrocyte sedimentation rate (ESR), C-reactive protein (CRP), Bath Ankylosing Spondylitis Disease Activity Index (BASDAI), and Bath Ankylosing Spondylitis Functional Index (BASFI). We found that hsa_circ_0003307 overexpression could promote the activation of the PI3K/AKT pathway and expression of inflammatory cytokines - tumor necrosis factor alpha (TNF-alpha) and TNF-alpha-induced protein 2 ( TNFAIP2). However, hsa_circ_ 0003307 knockdown reduced the expression of TNF-alpha and TNFAIP2. Conclusions. The expression level of hsa_circ_0003307 was associated with inflammatory response, and it was revealed that hsa_circ_0003307 knockdown could reduce the inflammatory response of AS by regulating the PI3K/AKT pathway.
- 11 March 2022
- Published by Wroclaw Medical University in Advances in Clinical and Experimental Medicine
- Vol. 31 (7) , 781-788
Open AccessKnockdown of circular RNA hsa_circ_0003307 inhibits synovial inflammation in ankylosing spondylitis by regulating the PI3K/AKT pathway
Background. Ankylosing spondylitis (AS) has a high disability rate, and an early diagnosis is difficult. Objectives. To explore the possible functions and underlying mechanism of circular RNAs Homo sapiens (hsa)_circ_0003307 in ankylosing spondylitis. Materials and methods. The hsa_circ_0003307 expression levels were investigated in the peripheral blood mononuclear cells (PBMCs) of 30 AS patients and 30 healthy controls (HC) using quantitative reverse transcription polymerase chain reaction (qRT-PCR) analysis. Primary fibroblast-like synoviocytes (FLS) were separated from synovial tissues, established as cell lines and cultured for subsequent cell experiments involving transfection with different vectors. The qRT-PCR analysis was used for evaluating the levels of hsa_circ_0003307 in AS-FLS. Phosphoinositide 3-kinase (PI3K)/protein kinase B (AKT) pathway-related protein levels were measured using western blotting and immunofluorescence. Enzyme-linked immunosorbent assay (ELISA) was used to detect the levels of inflammatory cytokines. Spearman's correlation analysis was used to assess the correlation between hsa_circ_0003307 and clinical characteristics. Results. The expression level of hsa_circ_0003307 was significantly high in AS patients and was positively associated with erythrocyte sedimentation rate (ESR), C-reactive protein (CRP), Bath Ankylosing Spondylitis Disease Activity Index (BASDAI), and Bath Ankylosing Spondylitis Functional Index (BASFI). We found that hsa_circ_0003307 overexpression could promote the activation of the PI3K/AKT pathway and expression of inflammatory cytokines - tumor necrosis factor alpha (TNF-alpha) and TNF-alpha-induced protein 2 ( TNFAIP2). However, hsa_circ_ 0003307 knockdown reduced the expression of TNF-alpha and TNFAIP2. Conclusions. The expression level of hsa_circ_0003307 was associated with inflammatory response, and it was revealed that hsa_circ_0003307 knockdown could reduce the inflammatory response of AS by regulating the PI3K/AKT pathway.